Upstream Bio, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

UPB$3.38-5.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Amounts in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Collaboration revenue	$773	$937	$1,807	$1,503
Operating expenses:
Research and development	36,089	37,865	72,654	63,662
General and administrative	7,052	7,419	15,136	14,201
Total operating expenses	43,141	45,284	87,790	77,863
Loss from operations	(42,368)	(44,347)	(85,983)	(76,360)
Other income (expense):
Interest income	2,659	4,431	5,713	9,174
Other income (expense), net	7	(50)	(23)	(50)
Total other income, net	2,666	4,381	5,690	9,124
Net loss	$(39,702)	$(39,966)	$(80,293)	$(67,236)
Net loss per share attributable to common stockholders, basic and diluted	$(0.73)	$(0.74)	$(1.47)	$(1.25)
Weighted-average common shares outstanding, basic and diluted	54,567,976	53,770,868	54,450,798	53,694,424
Comprehensive loss:
Net loss	$(39,702)	$(39,966)	$(80,293)	$(67,236)
Unrealized gain (loss) on investments, net of tax	(223)	(110)	(653)	283
Total other comprehensive income (loss)	(223)	(110)	(653)	283
Comprehensive loss	$(39,925)	$(40,076)	$(80,946)	$(66,953)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.